KR20230144935A - Functional food composition comprising chicory extracts, aged pumpkin fermentation and psyllium husk powder - Google Patents
Functional food composition comprising chicory extracts, aged pumpkin fermentation and psyllium husk powder Download PDFInfo
- Publication number
- KR20230144935A KR20230144935A KR1020230001026A KR20230001026A KR20230144935A KR 20230144935 A KR20230144935 A KR 20230144935A KR 1020230001026 A KR1020230001026 A KR 1020230001026A KR 20230001026 A KR20230001026 A KR 20230001026A KR 20230144935 A KR20230144935 A KR 20230144935A
- Authority
- KR
- South Korea
- Prior art keywords
- functional food
- food composition
- composition
- chicory
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 235000009854 Cucurbita moschata Nutrition 0.000 title claims abstract description 37
- 235000000832 Ayote Nutrition 0.000 title claims abstract description 35
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 title claims abstract description 35
- 235000015136 pumpkin Nutrition 0.000 title claims abstract description 35
- 235000013376 functional food Nutrition 0.000 title claims abstract description 28
- 239000000843 powder Substances 0.000 title claims abstract description 25
- 244000134552 Plantago ovata Species 0.000 title claims abstract description 19
- 235000003421 Plantago ovata Nutrition 0.000 title claims abstract description 19
- 239000009223 Psyllium Substances 0.000 title claims abstract description 19
- 239000010903 husk Substances 0.000 title claims abstract description 19
- 229940070687 psyllium Drugs 0.000 title claims abstract description 19
- 238000000855 fermentation Methods 0.000 title claims abstract description 13
- 230000004151 fermentation Effects 0.000 title claims abstract description 13
- 240000001980 Cucurbita pepo Species 0.000 title claims abstract description 11
- 244000298479 Cichorium intybus Species 0.000 title 1
- 241000723343 Cichorium Species 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 210000000056 organ Anatomy 0.000 claims abstract description 20
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 19
- 238000005728 strengthening Methods 0.000 claims abstract description 16
- 230000017531 blood circulation Effects 0.000 claims description 26
- 239000003963 antioxidant agent Substances 0.000 claims description 18
- 230000003579 anti-obesity Effects 0.000 claims description 16
- 230000036737 immune function Effects 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000006872 improvement Effects 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000003064 anti-oxidating effect Effects 0.000 claims description 2
- 238000011085 pressure filtration Methods 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 41
- 235000013305 food Nutrition 0.000 abstract description 27
- 150000002632 lipids Chemical class 0.000 abstract description 14
- 235000012000 cholesterol Nutrition 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 230000033001 locomotion Effects 0.000 abstract description 6
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 4
- 230000008602 contraction Effects 0.000 abstract description 3
- 230000007760 free radical scavenging Effects 0.000 abstract description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract 1
- 240000004244 Cucurbita moschata Species 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000010171 animal model Methods 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- 206010010774 Constipation Diseases 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013373 food additive Nutrition 0.000 description 7
- 239000002778 food additive Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- -1 cell membranes Proteins 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 235000009852 Cucurbita pepo Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000012812 general test Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 포함하는 기능성 식품 조성물에 관한 것으로, 본 발명에 따른 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 함유하는 식품 조성물은 DPPH 자유 라디칼 소거활성이 우수하여 항산화 효과가 있으며, 혈관의 수축을 억제하여 혈관 이완을 유도하는 효능이 있다. 또한, 콜레스테롤의 증가를 억제하여 혈액과 간의 지질을 감소시켜 비만 억제효과가 있으며, 장기기능을 강화하고 배변활동을 원활하게 하여 기능성 웰빙식품으로 매우 유용하게 이용될 수 있을 것으로 기대된다.The present invention relates to a functional food composition containing chicory extract, old pumpkin fermentation product, and psyllium husk powder as active ingredients. The food composition containing chicory extract, old pumpkin fermentation product, and psyllium husk powder as active ingredients according to the present invention is DPPH. It has excellent free radical scavenging activity, has an antioxidant effect, and has the effect of suppressing the contraction of blood vessels and inducing blood vessel relaxation. In addition, it has an obesity-suppressing effect by suppressing the increase in cholesterol and reducing lipids in the blood and liver. It is expected to be very useful as a functional wellness food by strengthening organ function and facilitating bowel movements.
Description
본 발명은 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 포함하는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물에 관한 것이다.The present invention relates to a functional food composition having antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening effects, characterized by containing chicory extract, fermented aged pumpkin and psyllium husk powder as active ingredients.
최근 생활과 소득 수준이 향상되면서 삶의 질을 향상시키기 위해 많은 관심이 높아지고 있다. 특히 노화와 각종 염증질환, 암의 대처 방안으로 항산화 물질을 비롯한 체내 질병과 대사를 위한 생리활성물질 개발에 대해 관심이 증대되었다 (KB Kim, et al., Journal of Nutrition and Health. 50(5);415-425(2017)). 생체 내에서 필요한 에너지 공급을 위해 생화학적 산화 반응은 끊임없이 일어나며 이 과정 중에 발생하는 유해산소라 불리어지는 활성산소 (reactive oxygen species, ROS)는 가장 안정한 형태의 산소인 삼중항산소가 산화, 환원과정에서 생성되는 일중항산소인 수퍼옥사이드 음이온(Superoxide anion), 하이드록실 라디칼(hydroxyl radical), 과산화수소(hydrogen peroxide)와 같은 불안정한 상태의 유리 라디칼(free radical) 및 과산화수소 (H2O2)로 불안정하고 산화력이 높아 생체물질과 쉽게 반응하기 때문에 인체 내에서 제거되지 못하면 산화적 스트레스 (oxidative stress)를 유발하게 된다. 이러한 산화적 스트레스는 염증반응과 연결되어 있으므로 여러 대사과정에서 지질과산화를 유도하고, 단백질, 세포막 및 DNA 등을 손상시켜 세포의 노화와 변형을 유도함으로써 뇌졸중, 암, 동맥경화, 알츠하이머병, 파킨슨병, 동맥경화증 등 다양한 질병을 유발한다 (Valko M, et al., Int J Biochem Cell Biol. 39:44-84(2007); 및 Halliwell B, et al., NY, USA. 968(1999)). 이렇게 생성된 활성탄소를 제거시켜 생체를 보호하는 생리학적 항산화 효소로는 수퍼옥사이드 디스무타제(superoxide dismutase, SOD), 카탈라제(catalase), 글루타치온-퍼옥시다제(glutathione-peroxidase, GSHpx) 및 글루타치온 S-트랜스퍼라제(glutathione S-transferase, GST) 등이 있으며, 저분자의 항산화제 혹은 유리 라디칼 소거역할을 하는 것으로 α-토코페롤, β-카로틴, 아스코브산 및 글루타치온 등이 알려져 있다 (Kim SM, et al., Life Sci. 90(21-22);874-882(2012)).Recently, as living and income levels have improved, there has been a growing interest in improving the quality of life. In particular, interest has increased in the development of bioactive substances for diseases and metabolism in the body, including antioxidants, as a way to combat aging, various inflammatory diseases, and cancer (KB Kim, et al., Journal of Nutrition and Health. 50(5) ;415-425(2017)). Biochemical oxidation reactions occur constantly to supply the energy needed in the living body, and reactive oxygen species (ROS), called harmful oxygen, generated during this process are triplet oxygen, the most stable form of oxygen, in the oxidation and reduction process. Superoxide anion, which is a singlet oxygen, and unstable free radicals such as hydroxyl radical and hydrogen peroxide, as well as hydrogen peroxide (H2O2), are unstable and have high oxidizing power, so they are harmful to living organisms. Because it reacts easily with substances, if it cannot be removed from the human body, it causes oxidative stress. Since this oxidative stress is linked to the inflammatory response, it induces lipid peroxidation in various metabolic processes and damages proteins, cell membranes, and DNA, thereby inducing cellular aging and deformation, leading to stroke, cancer, arteriosclerosis, Alzheimer's disease, and Parkinson's disease. , causes various diseases such as arteriosclerosis (Valko M, et al., Int J Biochem Cell Biol. 39:44-84 (2007); and Halliwell B, et al., NY, USA. 968 (1999)). Physiological antioxidant enzymes that protect living organisms by removing the activated carbon produced in this way include superoxide dismutase (SOD), catalase, glutathione-peroxidase (GSHpx), and glutathione S. -Transferase (glutathione S-transferase, GST), etc., and α-tocopherol, β-carotene, ascorbic acid, and glutathione are known to act as low-molecular-weight antioxidants or free radical scavengers (Kim SM, et al ., Life Sci. 90(21-22);874-882(2012)).
한편, 현대인은 식생활 패턴의 변화에 따라 지방질 섭취량은 많아짐에도 운동량은 상대적으로 부족하며, 각종 스트레스를 받으며 살아가고 있다. 이러한 식생활의 변화로 인해, 고혈압, 동맥경화 또는 혈액순환 장애 등의 질병이 증가하는 추세이다. 특히, 혈액순환 장애는 기억력 감퇴, 무기력, 집중력의 약화 및 만성 피로 등의 증상을 유발하는 것으로 알려져 있다. Meanwhile, modern people have increased fat intake due to changes in eating patterns, but they are relatively lacking in exercise and are living under various stresses. Due to these changes in eating habits, diseases such as high blood pressure, arteriosclerosis, or blood circulation disorders are on the rise. In particular, blood circulation disorders are known to cause symptoms such as memory loss, lethargy, weakness in concentration, and chronic fatigue.
혈액순환이란 체내의 혈액이 일정한 방향으로 유동하는 현상을 말하고, 혈액순환 장애는 혈관이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되고 노폐물 수치가 증가하여 혈액의 유동성이 저하하고, 혈관 내부가 좁아져 혈액순환이 원활하게 이루어지지 않는 현상을 의미한다.Blood circulation refers to the phenomenon in which the blood in the body flows in a certain direction. Blood circulation disorders are caused by blood vessels losing their elasticity, cholesterol, etc. being deposited on the inner walls, the level of waste products increasing, which reduces the fluidity of blood, and the inside of blood vessels narrows, leading to blood flow. This refers to a phenomenon in which circulation does not occur smoothly.
혈액순환 장애로 인해 유발되는 질병으로는, 고지혈증, 동맥경화, 심근경색 또는 뇌혈전증 등과 같은 심혈관계 질환이 있다. 심혈관계 질병 중에서도 고혈압, 동맥경화, 심장병 또는 뇌졸증 등은 노령층에서는 사망의 가장 큰 원인 중 하나로 꼽히고 있다.Diseases caused by blood circulation disorders include cardiovascular diseases such as hyperlipidemia, arteriosclerosis, myocardial infarction, or cerebral thrombosis. Among cardiovascular diseases, high blood pressure, arteriosclerosis, heart disease, or stroke are considered one of the biggest causes of death in the elderly.
이처럼 혈액순환 장애를 방치할 경우에는 정상적인 생활을 유지하는 데에 어려움을 주게 되고, 심할 경우에는 다양한 형태의 질환으로 발전되어 사망에 이를 수도 있다. 따라서, 혈액순환 장애로 인한 질병에 대한 치료보다는 예방이 중요하다고 볼 수 있다.If blood circulation disorders are left untreated, it becomes difficult to maintain a normal life, and in severe cases, it can develop into various types of diseases and even lead to death. Therefore, prevention of diseases caused by blood circulation disorders can be considered more important than treatment.
한편, 변비는 대장의 연동운동 저하로 원활한 배변 운동을 하지 못하는 질환이다. 일반적으로 1주일에 2회 이상를 배출하지 못하면 배변 시 굳은 변을 보며 통증이나 출혈이 동반되는 경우를 변비로 진단하는데, 그 증상으로는 일반적으로 하복부의 불쾌감, 팽만감, 구역질, 구토, 복통 등이 수반된다.Meanwhile, constipation is a disease that prevents smooth bowel movement due to decreased peristalsis in the large intestine. In general, if you are unable to excrete more than twice a week, you see hard stools during defecation and are accompanied by pain or bleeding, it is diagnosed as constipation. Symptoms include discomfort in the lower abdomen, bloating, nausea, vomiting, and abdominal pain. do.
하지만, 섭취하는 음식의 형태에 따라 배변시간에 영향을 나타내며, 특히 유산균은 장내에서 유산과 초산을 생성하여 딱딱해진 변을 부드럽게 만들어 배변을 원활하게 해준다.However, the type of food consumed affects defecation time. In particular, lactic acid bacteria produce lactic acid and acetic acid in the intestines to soften hard stools and facilitate defecation.
또한, 식이섬유는 인체의 소화효소에 의해 분해되지 않는 난소화성 복합 다당류로 식이섬유가 풍부한 식품을 섭취하면 배설물의 부피를 증가시킬 뿐만 아니라 음식물의 장 통과 속도를 빠르게 하여 변비를 예방하는데 도움을 주는 것으로 알려져 있다.In addition, dietary fiber is an indigestible complex polysaccharide that is not broken down by the body's digestive enzymes. Consuming foods rich in dietary fiber not only increases the volume of feces, but also helps prevent constipation by speeding up the passage of food through the intestines. It is known that
면역반응이란, 외부에서 우리 몸으로 들어오는 모든 물질에 대해서 나타나는 반응으로서 특히 살아있는 생명체인 미생물들이 질병의 발생과 직접적으로 또는 간접적으로 관련되어 있기 때문에, 이들에 대한 면역반응이 숙주에게 매우 중요하다. An immune response is a response to any substance that enters our body from the outside. In particular, since microorganisms, which are living organisms, are directly or indirectly related to the occurrence of diseases, the immune response to them is very important for the host.
현대 사회가 복잡해지고 발전된 산업으로 인한 여러 돌연변이 발암 원이 생활공간 가까이 접근되어 있고, 그러한 돌연변이 발암 원으로 인해 인체의 정상 유전자나 바이러스 등의 유전자의 변형이 더욱 가속화되었다. 결국 약품은 발전하였지만 면역세포는 유전자의 변형으로 인하여 그 기능이 약화되고 바이러스는 더욱 강해져 더욱더 많은 문제를 발생시키고 있다. 이와 같이 현대인의 식습관이나 환경의 오염으로 인한 면역력 저하는 더 강해진 바이러스, 외부의 미생물 등의 침입에 의해 야기되는 홍역 및 독감과 같은 전염성 질환, 암, 선천성기형, 면역계 결함 및 많은 치명적 질병에 쉽게 노출되는 결과를 초래한다.Due to the complexity of modern society and advanced industries, various mutant carcinogens are close to living spaces, and such mutant carcinogens have further accelerated the transformation of normal genes in the human body and genes such as viruses. Ultimately, drugs have advanced, but immune cells have weakened their functions due to genetic modification, and viruses have become stronger, causing more and more problems. In this way, modern people's weakened immunity due to their eating habits or environmental pollution easily exposes them to infectious diseases such as measles and flu, cancer, congenital malformations, immune system defects, and many fatal diseases caused by the invasion of stronger viruses and external microorganisms. leads to a result.
이에 본 발명자는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화 효능이 극대화된 조성물을 개발하기 위해 계속 연구를 진행하던 중 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말이 혼합된 조성물이 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효능을 가진다는 것을 발견함으로써 본 발명을 완성하였다. Accordingly, the present inventor continued research to develop a composition that maximized the effects of antioxidants, blood circulation improvement, anti-obesity, immune function, and organ function enhancement, and found that a composition containing chicory extract, aged pumpkin fermentation, and psyllium husk powder was found to be an antioxidant. The present invention was completed by discovering that it has the effect of improving blood circulation, anti-obesity, strengthening immune function and organ function.
따라서, 본 발명에서 해결하고자 하는 기술적 과제는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화 효능을 가지는 기능성 식품 조성물을 제공하기 위한 것이다. Therefore, the technical problem to be solved by the present invention is to provide a functional food composition that has antioxidant, blood circulation improvement, anti-obesity, immune function, and organ function strengthening effects.
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 포함하는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물을 제공한다.In order to solve the above-described technical problem, the present invention has antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening effects, characterized by containing chicory extract, fermented old pumpkin and psyllium husk powder as active ingredients. A functional food composition is provided.
바람직하게, 상기 기능성 식품 조성물은 치커리 추출물 100 중량부에 대하여 늙은 호박 발효물 50 내지 70 중량부 및 차전자피 분말 30 내지 50 중량부를 포함하는 것을 특징으로 한다.Preferably, the functional food composition is characterized in that it contains 50 to 70 parts by weight of fermented aged pumpkin and 30 to 50 parts by weight of psyllium husk powder based on 100 parts by weight of chicory extract.
바람직하게, 상기 치커리 추출물은 치커리를 동결건조하고 분쇄하여 90 내지 110℃의 정제수를 이용하여 50 내지 70분 동안 열수 추출한 다음 감압 여과 및 농축하여 수득되는 것을 특징으로 한다.Preferably, the chicory extract is obtained by freeze-drying and pulverizing chicory, performing hot water extraction using purified water at 90 to 110° C. for 50 to 70 minutes, followed by reduced pressure filtration and concentration.
바람직하게, 상기 치커리는 치커리 뿌리를 이용하는 것을 특징으로 한다.Preferably, the chicory is characterized by using chicory root.
바람직하게, 상기 늙은 호박 발효물은 37 내지 45℃에서 24 내지 48시간 동안 발효시켜 수득되는 것을 특징으로 한다.Preferably, the aged pumpkin fermentation product is obtained by fermenting at 37 to 45° C. for 24 to 48 hours.
이와 같이, 본 발명에 따른 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 함유하는 조성물은 DPPH 자유 라디칼 소거활성이 우수하여 항산화 효과가 있으며, 혈관의 수축을 억제하여 혈관 이완을 유도하는 효능이 있다. 또한, 콜레스테롤의 증가를 억제하여 혈액과 간의 지질을 감소시켜 비만 억제효과가 있으며, 장기기능을 강화하고 배변활동을 원활하게 하여 기능성 웰빙식품으로 매우 유용하게 이용될 수 있을 것으로 기대된다.As such, the composition containing chicory extract, aged pumpkin ferment, and psyllium husk powder as active ingredients according to the present invention has excellent DPPH free radical scavenging activity, has an antioxidant effect, and has the effect of inhibiting vascular contraction and inducing vascular relaxation. There is. In addition, it has an obesity-suppressing effect by suppressing the increase in cholesterol and reducing lipids in the blood and liver. It is expected to be very useful as a functional wellness food by strengthening organ function and facilitating bowel movements.
이하 본 발명을 좀더 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서는 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 포함하는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물을 제공한다.The present invention provides a functional food composition having antioxidant, blood circulation improvement, anti-obesity, immune function, and organ function strengthening effects, characterized by containing chicory extract, aged pumpkin fermentation, and psyllium husk powder as active ingredients.
본 발명의 하나의 구현예에 따르면, 상기 기능성 식품 조성물은 치커리 추출물 100 중량부에 대하여 늙은 호박 발효물 50 내지 70 중량부 및 차전자피 분말 30 내지 50 중량부를 포함하는 것을 특징으로 한다.According to one embodiment of the present invention, the functional food composition is characterized in that it contains 50 to 70 parts by weight of fermented pumpkin and 30 to 50 parts by weight of psyllium husk powder based on 100 parts by weight of chicory extract.
본 발명에서 사용하는 치커리에는 비타민 A, C, 칼륨, 인 등이 함유되어 있으며, 치커리 뿌리에는 이눌린이 다량 함유되어 있다. 이는 장내 미생물에 의해 발효되는 과정에서 단쇄 지방산을 생성하고, 생성된 단쇄 지방산은 다양한 경로를 통해 체내 콜레스테롤의 재흡수를 저해하고 변으로 배설하게 하여 콜레스테롤 수치를 낮추는 작용, 소화기관 내의 포도당 흡수를 감소시켜 식후 혈당상승 억제, 장내 균총을 개선하여 배변활동을 원활하게 하는 등 체내에 유익한 영향을 나타내는 것으로 알려져 있다.The chicory used in the present invention contains vitamins A, C, potassium, and phosphorus, and the chicory root contains a large amount of inulin. This produces short-chain fatty acids during fermentation by intestinal microorganisms, and the produced short-chain fatty acids inhibit the reabsorption of cholesterol in the body through various pathways and excrete it through stool, lowering cholesterol levels and reducing glucose absorption in the digestive tract. It is known to have beneficial effects on the body, such as suppressing the rise in blood sugar levels after a meal and improving intestinal flora to facilitate bowel movements.
본 발명에서는 치커리 뿌리를 이용하는 것을 특징으로 한다.The present invention is characterized by using chicory root.
본 발명의 용어 "추출물(extract)"은 생약을 적절한 침출액으로 짜내고 침출액을 증발시켜 농축한 제제를 의미하는 것으로, 이에 제한되지는 않으나, 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물일 수 있다. The term "extract" in the present invention refers to a preparation obtained by squeezing the herbal medicine into an appropriate leachate and evaporating the leachate to concentrate. It is not limited thereto, but includes the extract, diluted or concentrated liquid of the extract, or extract obtained through extraction treatment. It may be a dried product obtained by drying, a crude product thereof, or a purified product.
본 발명의 치커리 추출물은 당업계에 공지된 일반적인 추출방법, 분리 및 정제방법을 이용하여 제조할 수 있다. 상기 추출방법으로는 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있으나, 이에 제한되지는 않는다.The chicory extract of the present invention can be prepared using general extraction, separation and purification methods known in the art. The extraction method may include boiling water extraction, hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction, but is not limited thereto.
본 발명의 구체적인 실시양태에 따르면, 치커리 추출물은 천연 식물을 그대로 분쇄하여 사용하거나, 열풍건조기 또는 동결건조기를 이용하여 건조하여 분쇄한 후 추출용매, 예컨대 물, 탄소수 1~3개의 무수 또는 함수 저급 알콜 및 이들의 혼합용매로 이루어진 군에서 선택된 용매를 추출용매, 바람직하게는 물 또는 에탄올을 사용하여 추출할 수 있으며, 상기 추출 용매의 양은 천연 식물 건조 중량의 2 내지 20 중량배, 바람직하게는 5 내지 15 중량배로 할 수 있다.According to a specific embodiment of the present invention, the chicory extract can be used by pulverizing the natural plant as is, or drying and pulverizing it using a hot air dryer or freeze dryer and then using an extraction solvent such as water, anhydrous or hydrous lower alcohol having 1 to 3 carbon atoms. And a solvent selected from the group consisting of mixed solvents thereof can be extracted using an extraction solvent, preferably water or ethanol, and the amount of the extraction solvent is 2 to 20 times the dry weight of the natural plant, preferably 5 to 5 times. You can do this by 15 times the weight.
본 발명의 구체적인 실시태양에 따르면, 치커리 추출물은 천연 식물을 그대로 분쇄하여 사용하거나, 열풍건조기 또는 동결건조기를 이용하여 건조하여 분쇄한 후 물 또는 물과 알콜 혼합물을 사용하여 실온에서 2 내지 10일, 바람직하게는 7일 동안 추출한 다음, 여과지로 여과한 후 농축하여 물에 녹는 성분과 알콜에 녹는 성분 분리하여 물 용해성분과 알콜 용해성분을 5:4의 중량비로 혼합하여 각 천연 추출물을 각각 수득할 수 있다.According to a specific embodiment of the present invention, the chicory extract can be used by pulverizing the natural plant as is, or drying and pulverizing it using a hot air dryer or freeze dryer, and then using water or a mixture of water and alcohol at room temperature for 2 to 10 days. Preferably, the extract is extracted for 7 days, filtered through filter paper, concentrated, separated into water-soluble components and alcohol-soluble components, and the water-soluble components and alcohol-soluble components are mixed at a weight ratio of 5:4 to obtain each natural extract. there is.
구체적으로, 치커리를 분쇄하여 90 내지 110℃의 정제수를 이용하여 50 내지 70분 동안 열추출한 다음 감압 여과 및 농축하여 치커리 추출물을 획득할 수 있다.Specifically, chicory extract can be obtained by pulverizing chicory, heat-extracting it using purified water at 90 to 110°C for 50 to 70 minutes, and then filtering and concentrating under reduced pressure.
상기 치커리 추출물은 상기 수득된 추출액을 농축 및 동결건조를 통하여 수분을 완전히 제거시킨 것일 수 있으며, 상기 수분을 완전히 제거시킨 치커리 추출물은 분말형태로 사용하거나 상기 분말을 증류수 또는 통상의 용매에 녹여 사용할 수 있다.The chicory extract may be obtained by completely removing moisture from the obtained extract by concentrating and freeze-drying, and the chicory extract from which the moisture has been completely removed can be used in powder form or by dissolving the powder in distilled water or a common solvent. there is.
본 발명의 하나의 구현예에 따르면, 상기 치커리 추출물은 치커리 뿌리를 분쇄하여 수득된 분말에 90 내지 110℃의 정제수를 가하여 50 내지 70분 동안 열수 추출한 다음 감압 여과 및 농축한 다음 건조하여 분말화하여 수득되는 것을 특징으로 한다.According to one embodiment of the present invention, the chicory extract is obtained by pulverizing chicory roots, adding purified water at 90 to 110° C., extracting it with hot water for 50 to 70 minutes, followed by filtration and concentration under reduced pressure, followed by drying and powdering. It is characterized by being obtained.
상기 정제수는 치커리 분말에 대해 5 내지 8 부피배의 양으로 가하는 것을 특징으로 한다.The purified water is added in an amount of 5 to 8 times the volume of chicory powder.
상기 치커리 추출물은 유산균의 먹이가 되는 프리바이오틱스로서 사용되며, 본 발명의 기능성 조성물을 유산균과 함께 섭취할 경우 보다 기능성을 높을 수 있다.The chicory extract is used as a prebiotic that serves as food for lactic acid bacteria, and when the functional composition of the present invention is consumed together with lactic acid bacteria, the functionality can be higher.
본 발명의 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화 효능을 가지는 조성물의 유효성분인 호박(Cucurbita spp.)은 박과에 속하는 일년생 덩굴성 초본으로 동양계 호박(C. moschata), 서양계 호박(C. maxima), 페루계 호박(C. pepo)으로 나뉜다. 최근 국내에서 건강식품으로 각광받고 있는 단호박(kabocha squash)은 쿠쿨비타 막시마 더치(Cucurbita maxima Duch)라고도 하고, 서양계 호박에 속한다. 단호박은 고랭지 작물로 1.5 ㎏ 내외의 작은 크기로 진한 녹색의 과피를 가지고 있고, 진황색을 띤 과육은 두껍고 치밀하다. 중량에 있어서는 과육 부위가 84%, 껍질이 10%, 내부 섬유상 물질이 3.5%를 차지하고 있으며, 유리당, 유리아미노산, 유기산, 총 카로티노이드 등의 조성 및 함량이 호박의 부위에 따라 차이가 있다.Pumpkin (Cucurbita spp.), the active ingredient of the composition of the present invention with antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening effects, is an annual climbing herb belonging to the Cucurbitaceae family, including Asian pumpkin (C. moschata), It is divided into Western pumpkin (C. maxima) and Peruvian pumpkin (C. pepo). Kabocha squash, which has recently been in the spotlight as a health food in Korea, is also called Cucurbita maxima Duch and belongs to the Western pumpkin family. Sweet pumpkin is a highland crop, small in size (about 1.5 kg), has a dark green skin, and the dark yellow flesh is thick and dense. By weight, the flesh accounts for 84%, the peel 10%, and the internal fibrous material 3.5%, and the composition and content of free sugars, free amino acids, organic acids, and total carotenoids differ depending on the part of the pumpkin.
단호박은 90년대 후반부터 국내에 재배가 급증하였고 β-카로틴의 함량이 높을 뿐만 아니라 특히 비타민 A와 카로티노이드류, 다양한 비타민류, 칼슘, 나트륨, 인이 풍부한 섬유질을 함유하고 있으며, 구성 당류의 소화 흡수율도 높다. 또한 단호박의 경우 호박에 비해 고형질 함량이 월등히 높고, 아르기닌, 티로신, 시스틴, 아스파르트산 등의 필수아미노산과 올레산, 리놀레산 등의 불포화 지방산이 풍부하게 들어 있어 영양적·기능적인 식품 소재로 각광받고 있다.Sweet pumpkin cultivation has increased rapidly in Korea since the late 1990s, and not only does it have a high content of β-carotene, but it also contains fiber, especially vitamin A, carotenoids, various vitamins, calcium, sodium, and phosphorus, and has a high digestibility and absorption rate of its constituent sugars. is also high. In addition, sweet pumpkin has a much higher solid content than pumpkin, and is rich in essential amino acids such as arginine, tyrosine, cystine, and aspartic acid, and unsaturated fatty acids such as oleic acid and linoleic acid, so it is attracting attention as a nutritious and functional food material. .
단호박은 다른 과채류에 비해 기후조건에 대한 적용범위가 넓고, 기후 풍로에서 장래 생산 가능성이 높으며, 기온차가 비교적 높은 곳에서도 생육이 양호하여 병해충에 강하고 기타 생육에 필요한 약제를 살포할 필요가 거의 없는 무공해 식품으로 그 가치가 높기 때문에 대체작목으로 각광을 받고 있고 재배면적도 증가하고 있는 추세이다.Compared to other fruits and vegetables, sweet pumpkin has a wider range of application to climatic conditions, has a high possibility of future production in climatic environments, grows well even in places with relatively high temperature differences, is resistant to diseases and pests, and is pollution-free with little need for spraying other chemicals necessary for growth. Because of its high value as food, it is receiving attention as an alternative crop, and its cultivation area is also increasing.
본 발명의 하나의 구현예에 따르면, 늙은 호박 발효물을 사용하는 것을 특징으로 하며, 늙은 호박 발효물은 당분야의 통상의 방법에 따라 제조될 수 있으며, 시판하는 늙은 호박 발효물을 사용하거나 또는 늙은 호박 분말을 37 내지 45℃에서 5 내지 10일 동안 발효시킴으로써 수득될 수 있다. According to one embodiment of the present invention, it is characterized in that aged pumpkin fermentation product is used, and the old pumpkin fermentation product can be prepared according to a conventional method in the art, and a commercially available old pumpkin fermentation product is used, or It can be obtained by fermenting aged pumpkin powder at 37 to 45°C for 5 to 10 days.
본 발명에 포함되는 차전자피 (질경이씨의 껍질; Psyllium husk)는 불용성 및 수용성 식이섬유를 함유하고 있으며, 점액을 형성하는 arabino-xylan-polysaccharide를 다량 함유하고 있어서 수분 보유량이 뛰어나다. 이러한 특성으로 변의 수분함량과 변의 부피를 증가시켜 배변활동을 도와주며 혈청 콜레스테롤과 LDL-콜레스테롤 농도를 낮추는 효과가 있다.Psyllium husk included in the present invention contains insoluble and soluble dietary fiber and contains a large amount of arabino-xylan-polysaccharide, which forms mucus, and has excellent moisture retention. These characteristics increase the water content and volume of stool, helping bowel movements and lowering serum cholesterol and LDL-cholesterol concentrations.
본 발명의 하나의 구현예에 따르면, 상기 기능성 식품 조성물은 치커리 추출물 100 중량부에 대하여 늙은 호박 발효물 50 내지 70 중량부 및 차전자피 분말 30 내지 50 중량부를 포함하는 것을 특징으로 한다. 이 때 상기 범위를 벗어날 경우 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화 효과를 수득하기 어렵다.According to one embodiment of the present invention, the functional food composition is characterized in that it contains 50 to 70 parts by weight of fermented pumpkin and 30 to 50 parts by weight of psyllium husk powder based on 100 parts by weight of chicory extract. At this time, if it is outside the above range, it is difficult to obtain the effects of antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening.
본 명세서에서 용어 '유효성분으로 포함하는'이란 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말의 효능 또는 활성을 달성하는데 충분한 양을 포함하는 것을 의미한다. As used herein, the term 'comprising an active ingredient' means including an amount sufficient to achieve the efficacy or activity of chicory extract, aged pumpkin fermentation product, and psyllium husk powder.
본 발명에서 사용되는 용어 "예방"이란 본 발명에 따른 조성물의 투여에 의해 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화와 관련된 질병의 발생, 확산 및 재발을 억제 또는 지연시키는 모든 행위를 의미하고, 본 발명에서 사용된 용어 "치료"란 본 발명의 조성물의 투여로 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화와 관련된 질병의 진행이 지연 또는 멈춰 증세를 호전시키거나, 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능을 이롭게 변경하는 모든 행위를 의미한다. 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면, 대한의학협회 등에서 제시된 자료를 참조하여 본 발명의 조성물이 효과가 있는 질환의 정확한 기준을 알고, 개선, 향상 및 치료된 정도를 판단할 수 있을 것이다.The term "prevention" used in the present invention refers to any act of suppressing or delaying the occurrence, spread and recurrence of diseases related to antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening by administration of the composition according to the present invention. The term "treatment" used in the present invention means that the administration of the composition of the present invention improves symptoms by delaying or stopping the progression of diseases related to antioxidants, improving blood circulation, anti-obesity, strengthening immune function and organ function. , Antioxidation, blood circulation improvement, anti-obesity, and all actions that beneficially change immune function and organ function. Anyone with ordinary knowledge in the technical field to which the present invention pertains can know the exact criteria for diseases for which the composition of the present invention is effective and determine the degree of improvement, enhancement, and treatment by referring to the data presented by the Korean Medical Association, etc. There will be.
본 발명의 구체적인 일례에 따르면, 본 발명의 상기 조성물은 혈액순환 개선용일 수 있으며, 혈관 질환의 예방, 증상의 경감 또는 예방에 효과적인 조성물일 수 있다. 본 발명에 따른 조성물은 혈전생성 방지, 혈관수축 억제 및/또는 콜레스테롤 억제 효능이 인정된다. 구체적으로는, 상기 조성물은 항혈전 효능에 기인하는 혈액순환 개선용일 수 있으며, 비만, 당뇨 및 고지혈증 등을 포함하는 혈관 질환의 예방, 증상의 완화 또는 치료에 효과적인 조성물일 수 있다. 상기 혈관 질환은, 예를 들어, 비만, 당뇨, 뇌졸증, 뇌출혈, 동맥경화, 협심증, 심근경색, 고혈압, 빈혈, 편두통 또는 고지혈증 등을 포함한다.According to a specific example of the present invention, the composition of the present invention may be for improving blood circulation, and may be an effective composition for preventing, alleviating or preventing symptoms of vascular disease. The composition according to the present invention is recognized for its effectiveness in preventing thrombosis, inhibiting vasoconstriction, and/or inhibiting cholesterol. Specifically, the composition may be used to improve blood circulation due to its anti-thrombotic effect, and may be effective in preventing, alleviating symptoms, or treating vascular diseases including obesity, diabetes, and hyperlipidemia. The vascular disease includes, for example, obesity, diabetes, stroke, cerebral hemorrhage, arteriosclerosis, angina pectoris, myocardial infarction, hypertension, anemia, migraine, or hyperlipidemia.
본 발명의 일 구현예에 있어서, 상기 식품 조성물은 정제, 캡슐제, 분말, 과립, 액상, 환, 액제, 시럽, 즙, 현탁제, 유제, 또는 점적제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등 과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.In one embodiment of the present invention, the food composition may be tablets, capsules, powders, granules, liquids, pills, liquids, syrups, juices, suspensions, emulsions, or drops. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic, acceptable inert carrier such as ethanol, glycerol, water, etc. Additionally, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacance or sodium oleate, sodium stearate, magnesium stearate, sodium Includes benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc. Acceptable pharmaceutical carriers for compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these ingredients can be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents can be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants can be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
또한, 본 발명의 식품 조성물은 기능성 식품으로 이용하거나, 각종 식품에 첨가될 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 차류, 음료류, 육류, 초코렛, 젤리, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.Additionally, the food composition of the present invention can be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, tea, beverages, meat, chocolate, jelly, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, and There are health supplements, etc.
또한, 상기 식품 조성물은 상기 유효성분 외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition, the food composition contains, in addition to the active ingredients, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof, It may contain alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.
본 발명의 건강 기능성 식품은 정제, 캅셀, 분말, 과립, 스틱 액상, 환 등의 형태로 제조 및 가공할 수 있다.The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, stick liquid, pills, etc.
본 발명에서 건강기능식품이라 함은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, health functional food refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with the Health Functional Food Act, and refers to food that regulates nutrients or provides physiological properties for the structure and function of the human body. It means ingestion for the purpose of obtaining useful effects for health purposes such as action.
본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional food of the present invention may contain common food additives, and its suitability as a food additive is determined in accordance with the general provisions and general test methods of the food additive code approved by the Food and Drug Administration, unless otherwise specified. Judgment is made according to specifications and standards.
상기 식품 첨가물 공전에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정 셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다.Examples of items listed in the Food Additives Code include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, high-quality pigment, and guar gum; Mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations are included.
예를 들어, 정제 형태의 건강기능식품은 유효성분을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다.For example, for health functional foods in the form of tablets, a mixture of active ingredients with excipients, binders, disintegrants, and other additives is granulated in a conventional manner, and then a lubricant is added and compression molded, or the mixture is directly manufactured. Can be compression molded. In addition, the health functional food in the form of tablets may contain flavoring agents, etc., if necessary.
캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 상기 추출물을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among capsule-type health functional foods, hard capsules can be manufactured by filling a regular hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules can be prepared by mixing the extract with additives such as excipients. The mixture can be prepared by filling it into a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary.
환 형태의 건강기능식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다.The health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention and excipients, binders, disintegrants, etc., using a known method. If necessary, it can be coated with white sugar or other coating agent. Alternatively, the surface can be coated with substances such as starch or talc.
과립 형태의 건강기능식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.Health functional food in the form of granules can be manufactured into granules by mixing the active ingredient of the present invention with excipients, binders, disintegrants, etc., using a known method, and can contain flavoring agents, flavoring agents, etc., if necessary. there is.
본 발명의 조성물의 제조에는 식품 조성물로서 본 발명에서 소개하는 유효성분 이외에도 통상적으로 사용되는 식품 조성물과 같이 여러 향미제 및 천연 탄수화물을 추가 성분으로 함유할 수 있고, 생리학적으로 허용되는 보조제를 사용할 수 있으며, 해당 보조제에는 부형제, 감미제, 피복제, 팽창제, 윤활제, 결합제 또는 향미제 등을 사용할 수 있다.In the preparation of the composition of the present invention, in addition to the active ingredients introduced in the present invention as a food composition, various flavoring agents and natural carbohydrates may be added as additional ingredients, like commonly used food compositions, and physiologically acceptable auxiliaries may be used. The auxiliaries may include excipients, sweeteners, coating agents, leavening agents, lubricants, binders, or flavoring agents.
본 발명의 식품조성물은 기능성 식품으로 이용하거나, 각종 식품에 첨가될 수 있다. 본 발명에서 첨가한 조성물을 첨가할 수 있는 식품을 예를 들면, 초코렛류, 음료류, 식품류, 스낵류, 면류, 껌류, 사탕류 및 건강보조식품 등이 있다.The food composition of the present invention can be used as a functional food or added to various foods. Foods to which the composition added in the present invention can be added include, for example, chocolates, beverages, foods, snacks, noodles, gums, candies, and health supplements.
본 발명에서의 건강기능식품은 통상적으로 사용되는 식품 첨가물이 포함될 수 있으며, 식품 첨가물은 식품의약품안전청에서 승인된 식품 첨가물 공전의 총칙 및 일반시험법에 따라 규격 및 기준에 의하여 판정한다.The health functional food in the present invention may contain commonly used food additives, and the food additives are determined according to specifications and standards in accordance with the general rules and general test methods of the food additive code approved by the Food and Drug Administration.
이와 같이, 본 발명에 따른 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 함유하는 조성물은 DPPH 자유 라디칼 소거활성이 우수하여 항산화 효과가 있으며, 혈관의 수축을 억제하여 혈관 이완을 유도하는 효능이 있다. 또한, 콜레스테롤의 증가를 억제하여 혈액과 간의 지질을 감소시켜 비만 억제효과가 있으며, 장기기능을 강화하고 배변활동을 원활하게 하여 기능성 웰빙식품으로 매우 유용하게 이용될 수 있을 것으로 기대된다.As such, the composition containing chicory extract, aged pumpkin ferment, and psyllium husk powder as active ingredients according to the present invention has excellent DPPH free radical scavenging activity, has an antioxidant effect, and has the effect of inhibiting vascular contraction and inducing vascular relaxation. There is. In addition, it has an obesity-suppressing effect by suppressing the increase in cholesterol and reducing lipids in the blood and liver. It is expected to be very useful as a functional wellness food by strengthening organ function and facilitating bowel movements.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다. Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
<제조예 1> 치커리 추출물의 제조<Preparation Example 1> Preparation of chicory extract
치커리 뿌리 분말 1㎏을 정제수에 넣고 100℃에서 1시간 동안 열추출하여 치커리 추출물을 수득하였다. 상기 추출물을 어드벤텍 2호(Advantec No. 2, 110mm) 여과지로 감압 여과하여 불용성 물질을 제거한 후 냉각 콘덴서가 장착된 농축기를 사용하여 40℃에서 감압 농축하였다. 감압 농축된 추출물의 용매를 완전히 제거하기 위하여 정제수 0.5ℓ를 넣어 현탁시킨 후 동결건조기를 이용하여 치커리 추출물을 획득하였다.1 kg of chicory root powder was added to purified water and heat-extracted at 100°C for 1 hour to obtain a chicory extract. The extract was filtered under reduced pressure with Advantec No. 2 (110 mm) filter paper to remove insoluble substances, and then concentrated under reduced pressure at 40°C using a concentrator equipped with a cooling condenser. In order to completely remove the solvent from the extract concentrated under reduced pressure, 0.5 L of purified water was added to suspend it, and then a chicory extract was obtained using a freeze dryer.
<실시예 1> 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 함유하는 조성물의 제조<Example 1> Preparation of a composition containing chicory extract, fermented pumpkin and psyllium husk powder as active ingredients
상기 제조예 1에서 제조된 치커리 추출물 100 중량부에 대하여 늙은 호박 발효물 60 중량부 및 차전자피 분말 40 중량부를 포함하는 조성물을 제조하였다.A composition containing 60 parts by weight of fermented pumpkin and 40 parts by weight of psyllium husk powder was prepared based on 100 parts by weight of the chicory extract prepared in Preparation Example 1.
<비교예 1> <Comparative Example 1>
치커리 추출물만을 상기 실시예 1의 유효성분 총중량과 동일 양으로 포함하는 조성물을 제조하였다.A composition containing only chicory extract in an amount equal to the total weight of the active ingredients of Example 1 was prepared.
<비교예 2> <Comparative Example 2>
늙은 호박 발효물 및 차전자피 분말만을 상기 실시예 1의 유효성분 총중량과 동일 양으로 포함하는 조성물을 제조하였다.A composition containing only fermented aged pumpkin and psyllium husk powder in an amount equal to the total weight of the active ingredients of Example 1 was prepared.
<시험예 1> 항산화 효과 측정<Test Example 1> Measurement of antioxidant effect
(1) DPPH (1-1-diphenyl-2-picryl-hydrazyl) 라디칼 전자공여능 측정(1) Measurement of DPPH (1-1-diphenyl-2-picryl-hydrazyl) radical electron donating ability
상기 실시예 1에서 수득된 조성물 100㎕에 DPPH 용액 (5x10-4 M) 100㎕를 넣고 25℃ 인큐베이터에서 30분간 반응시킨 후 마이클로플레이트 계수기를 이용하여 540nm에서 흡광도를 측정하였으며 실험 대조구로는 L-아스코브산을 사용하였다. 전자공여능은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.100 μl of DPPH solution (5x10-4 M) was added to 100 μl of the composition obtained in Example 1, reacted for 30 minutes in an incubator at 25°C, and the absorbance was measured at 540 nm using a microplate counter. L was used as an experimental control. -Ascorbic acid was used. The electron donating ability was expressed as the rate of decrease in absorbance of the sample solution with and without addition.
상기 표 1에서 보듯이, 본 발명에 따른 실시예 1의 조성물은 98.3%의 높은 항산화 효과를 나타내었다.As shown in Table 1, the composition of Example 1 according to the present invention showed a high antioxidant effect of 98.3%.
(2) ABTS 양이온 라디칼 소거능 (cation radical scavenging activity) 측정(2) ABTS cation radical scavenging activity measurement
7mM 2,2-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid)와 2.4mM 과황산칼륨을 혼합하여 실온에서 24시간 동안 방치하여 ABTS+를 형성시킨 후 에탄올로 희석하여 ABTS+ 100㎕에 시료 100㎕를 가하여 1분동안 방치한 후 732nm에서 흡광도를 측정하였으며, 실험 대조구로는 L-아스코브산을 사용하였다. 라디칼 소거능은 1/2로 환원시키는데 필요한 시료의 농도 값으로 나타내었다.ABTS+ was formed by mixing 7mM 2,2-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid) and 2.4mM potassium persulfate and leaving at room temperature for 24 hours. Then, diluted with ethanol and added to 100㎕ of ABTS+. After adding 100㎕ and leaving it for 1 minute, the absorbance was measured at 732nm, and L-ascorbic acid was used as an experimental control. The radical scavenging ability was expressed as the concentration of the sample required to reduce it to 1/2.
ABTS+· 측정 결과, 본 발명에 따른 실시예 1의 조성물은 86.7%의 높은 항산화 효과를 나타내었다.As a result of ABTS+··measurement, the composition of Example 1 according to the present invention showed a high antioxidant effect of 86.7%.
<시험예 2> 혈관 이완 효과 측정<Test Example 2> Measurement of blood vessel relaxation effect
상기 실시예 1에서 제조한 조성물 및 비교예 1 및 2에서 제조된 조성물의 혈관 이완효과를 확인하기 위하여 돼지 심장의 관상동맥의 이완효과를 측정하였다. In order to confirm the vascular relaxation effect of the composition prepared in Example 1 and the composition prepared in Comparative Examples 1 and 2, the relaxation effect of the coronary arteries of the pig heart was measured.
먼저, 도축장에서 도살 직후의 돼지 심장을 구입한 후 관상동맥을 적출하여 18 mM NaCl, 47 mM KCl, 11 mM MgSO4, 12 mM KH2PO4, 15 mM CaCl2, 25 mM NaHCO3, 10 mM glucose가 들어있는 크렙스(Krebs) 용액(pH 7.4)에 넣고 연결조직과 지방을 제거한 후 약 3 mm의 길이의 절편으로 만들었다. First, after purchasing a pig heart immediately after slaughter at a slaughterhouse, the coronary artery was removed and 18mM NaCl, 47mM KCl, 11mM MgSO 4 , 12mM KH 2 PO 4 , 15mM CaCl 2 , 25mM NaHCO 3 , 10mM It was placed in Krebs solution (pH 7.4) containing glucose, connective tissue and fat were removed, and slices of about 3 mm in length were made.
그 다음 상기 관상동맥을 95% O2 및 5% CO2 기체로 포화시킨 37℃의 크렙스 용액에 고정시킨 후, 트롬복산 유도체인 U46619(1-60 nM)로 혈관최고수축의 80%로 10분 동안 수축시켰다. 그 다음 300 nM의 브레드키닌(Bradykinin)으로 이완 반응시켜 혈관 내피세포의 안정성을 측정한 후, 크렙스 용액으로 3회 세척하였다.Next, the coronary artery was fixed in Krebs solution at 37°C saturated with 95% O 2 and 5% CO 2 gas, and then treated with U46619 (1-60 nM), a thromboxane derivative, at 80% of peak vascular constriction for 10 minutes. It was contracted for a while. Next, the stability of vascular endothelial cells was measured by a relaxation reaction with 300 nM of bradykinin, and then washed three times with Krebs solution.
그 다음 상기 안정성을 측정한 관상동맥에 U45519로 수축시킨 후 상기 실시예 1에서 제조한 조성물을 처리하여 등척성 장력(isometric tension)을 힘-변위 변환기(force-displacement transducer, HugoSachs, Germany)가 장착된 생리기록계(Grass physiograph, HugoSachs, Germany)를 이용하여 혈관이완 효과 변화를 측정하였다. Next, the coronary artery whose stability was measured was contracted with U45519 and then treated with the composition prepared in Example 1 to generate isometric tension using a force-displacement transducer (HugoSachs, Germany). Changes in vasorelaxation effect were measured using a physiograph (Grass physiograph, HugoSachs, Germany).
대조군으로는 종래 혈관보호제로 사용되는 은행잎 추출물을 사용하였다. 혈관이완효과 변화 측정은 매 시료마다 3회 반복 측정하여 평균과 표준편차로 표기하였으며, ED50 값은 수축된 혈관이 시료처리에 의해 50%의 혈관 이완을 나타내는 시료의 농도(㎍/ml)를 의미한다. 그 결과를 표 3에 나타내었다.As a control group, ginkgo leaf extract, which is conventionally used as a vascular protective agent, was used. The change in vascular relaxation effect was measured three times for each sample and expressed as the average and standard deviation. The ED50 value refers to the concentration (㎍/ml) of the sample showing 50% vascular relaxation of the constricted blood vessels by sample treatment. do. The results are shown in Table 3.
상기 표 3에 나타낸 바와 같이 실시예 1의 조성물은 대조군(은행잎 추출물)에 비하여 약 3배 정도의 혈관 이완 효과를 나타내어, 본 발명에 따른 조성물의 높은 혈과 이완 효능을 확인할 수 있었다. As shown in Table 3, the composition of Example 1 exhibited a blood vessel relaxation effect about three times that of the control group (gingko leaf extract), confirming the high blood pressure and relaxation efficacy of the composition according to the present invention.
<시험예 3> 마우스 비장 내 T-림프구 및 B-림프구 증식능 평가<Test Example 3> Evaluation of T-lymphocyte and B-lymphocyte proliferation ability in mouse spleen
본 발명의 실시예 1의 조성물이 비장 내 면역세포인 T-림프구와 B-림프구 증식에 미치는 영향을 알아보았다.The effect of the composition of Example 1 of the present invention on the proliferation of T-lymphocytes and B-lymphocytes, which are immune cells in the spleen, was examined.
실험동물은 7주령 암컷 C57BL/6 마우스(오리엔트 바이오, 경기도 가평군, 대한민국)를 사용하였으며, 각 시험군당 6마리씩 총 30마리를 사용하였다. 구입한 동물은 온도 21±3℃, 상대습도 50±5%, 조도 200-300 룩스(Lux) 조건의 실험실에서 일주일 간 적응기간을 거친 후 시험에 사용하였으며, 시험에 사용된 동물들 모두에서 심한 체중변화나 이상반응은 관찰되지 않았다. 모든 시료는 생리식염수(중외제약, 대한민국)를 사용하여 현탁하였으며, 시료의 투여는 100 mg/kg씩 하루 1회, 총 7일간 경구 투여하였다. 정상대조군은 동량의 생리식염수를 같은 방법으로 투여하였다. 투여가 끝난 실험동물로부터 비장을 적출하여 비장세포를 분리한 다음, 96 웰 플레이트에 세포를 5X105 cells/well로 접종하였다. 이 후 T-림프구 증식능 측정을 위해서 각 웰에 5 ㎍/ml 농도의 concanavalin A (Con A; Sigma Aldrich, St. Louis, MO, USA) 용액을, B-림프구 증식능 측정을 위해서 15 ㎍/ml 농도의 LPS(Sigma Aldrich, St. Louis, MO, USA) 용액을 각각 10 ㎕씩 첨가하여 37℃, 5% CO2 인큐베이터에서 72시간 반응시켰다. 반응이 끝난 세포 배양액에 Cell titer 용액 (Promega, USA)을 20 ㎕씩 첨가하여 4시간 추가 배양한 다음, fluorescence Multi-Detection Reader ((BIO-TEK Instruments Inc., Power wave X340, Winooski, VT, USA)를 이용하여 490 nm에서 흡광도를 측정하였다.The experimental animals used were 7-week-old female C57BL/6 mice (Orient Bio, Gapyeong-gun, Gyeonggi-do, Korea), and a total of 30 mice were used, 6 for each test group. The purchased animals were used for testing after an acclimatization period of one week in a laboratory with a temperature of 21 ± 3°C, relative humidity of 50 ± 5%, and illumination of 200-300 Lux. All of the animals used in the test suffered severe damage. No weight changes or adverse reactions were observed. All samples were suspended using physiological saline (Jungwae Pharmaceutical, Korea), and the samples were administered orally at 100 mg/kg once a day for a total of 7 days. The normal control group was administered the same amount of physiological saline in the same manner. The spleen was removed from the experimental animal after administration, the spleen cells were isolated, and the cells were inoculated into a 96-well plate at 5X10 5 cells/well. Afterwards, concanavalin A (Con A; Sigma Aldrich, St. Louis, MO, USA) solution at a concentration of 5 ㎍/ml was added to each well to measure T-lymphocyte proliferation ability, and for measurement of B-lymphocyte proliferation ability, a solution of 15 ㎍/ml was added to each well. 10 ㎕ of LPS (Sigma Aldrich, St. Louis, MO, USA) solution was added to each solution and reacted at 37°C in a 5% CO2 incubator for 72 hours. 20 ㎕ of Cell titer solution (Promega, USA) was added to the reacted cell culture medium and cultured for an additional 4 hours, followed by fluorescence Multi-Detection Reader ((BIO-TEK Instruments Inc., Power wave X340, Winooski, VT, USA ) was used to measure the absorbance at 490 nm.
그 결과, 하기 표 4에 나타낸 바와 같이, T-림프구 및 B-림프구 증식 정도는 본 발명의 실시예 1의 조성물 투여군에서 증가됨을 확인하였다. As a result, as shown in Table 4 below, it was confirmed that the degree of T-lymphocyte and B-lymphocyte proliferation was increased in the group administered the composition of Example 1 of the present invention.
<시험예 4> 장기능 개선 및 변비 개선효과 <Test Example 4> Effect of improving intestinal function and constipation
실시예 1에서 제조된 조성물의 장기능 개선 및 변비 개선에 대한 효과를 알아보기 위하여 하기와 같은 방법을 수행하여 실시하였다.In order to determine the effect of the composition prepared in Example 1 on improving intestinal function and constipation, the following method was performed.
배변량을 측정하기 위해, 동물모델로 웅성의 평균 체중 220-240g 정도의 스프라그 도울리(Sprague Dawley) 랫트 (대한바이오링크, 음성)를 1군당 8 내지 10 마리를 사용하여 대사 케이지에서 3일간 순화 적응시키고, 4일째부터 변비를 유발시키기 위해 로페라마이드 (Sigma사, 미국)를 사료 3g당 1mg 함유하는 사료를 공급하였다. 대조군(로페라마이드군 처리군)은 식수만을 공급하였으며, 생약 조성물은 3.2㎎/㎖ 농도로 식수에 녹여 공급하여 실험 종료시까지 투여하였다. 변은 매일 채취하여 무게를 측량하였다.To measure the amount of defecation, Sprague Dawley rats (Daehan Biolink, Eumseong) with an average male weight of about 220-240 g were used as animal models (8 to 10 rats per group) and were acclimatized in a metabolic cage for 3 days. After adaptation, feed containing 1mg of loperamide (Sigma, USA) per 3g of feed was supplied to induce constipation from the 4th day. The control group (loperamide treatment group) was supplied only with drinking water, and the herbal medicine composition was dissolved in drinking water at a concentration of 3.2 mg/ml and administered until the end of the experiment. Stools were collected daily and weighed.
조성물의 변비 개선 효과를 실험한 결과, 대조군에 비하여 변비유발 기간동안에 배변량을 증가시켜 변비개선 효과가 있음을 확인하였다.As a result of testing the composition's effect on improving constipation, it was confirmed that it had an effect on improving constipation by increasing the amount of defecation during the constipation-inducing period compared to the control group.
<시험예 5> 체중 및 혈중 콜레스테롤 감소 실험<Test Example 5> Weight and blood cholesterol reduction experiment
실험동물로 ICR 마우스를 이용하여, 상기 실시예 1의 조성물을 재료로 한 시험대조군과 정상군을 식이 급여하며 사육 비교하였다.Using ICR mice as experimental animals, a test control group made from the composition of Example 1 and a normal group were fed and raised and compared.
본 실험에서 기본 식이는 AIN-76을 기본으로 단백질급원은 카제인(Japan), 탄수화물급원은 옥수수전분(제일제당), 지방급원으로 옥수수유(대상)을 사용한 정상군과 시험대조군을 비교하는 방식으로 진행하였다. 본 실험에 사용한 식품 조성물은 매일 일정시간에 1 ml씩 경구 급여하였으며 식이와 식수는 임의로 자유롭게 섭취하도록 하였다. 시험동물 사육환경은 항온(20±2℃), 항습(50±5%)하고 12 시간 광주기로 일정 조건을 유지하면서 폴리카보네이트 케이지에서 2 마리씩 분리하여 사육하였다. 동물에서 콜레스테롤은 혈류를 따라 순환하며 몇몇 기관에서 합성되며 혈류 내에서 콜레스테롤 수치가 크면 동맥경화의 주요 원인이 되므로 분석항목은 (1) 체중변화 및 식이섭취량, (2) 혈중 콜레스테롤 및 중성지질을 측정하는 것으로 진행하였다. In this experiment, the basic diet was AIN-76, the protein source was casein (Japan), the carbohydrate source was corn starch (CheilJedang), and the fat source was corn oil (target), and the normal group and test control group were compared. proceeded. The food composition used in this experiment was administered orally in 1 ml at a certain time every day, and food and drinking water were freely consumed. The test animals were raised separately in polycarbonate cages, maintaining constant conditions of constant temperature (20 ± 2°C), constant humidity (50 ± 5%), and a 12-hour photoperiod. In animals, cholesterol circulates through the bloodstream and is synthesized in several organs. If the cholesterol level in the bloodstream is high, it is a major cause of arteriosclerosis. Therefore, the analysis items are (1) weight change and dietary intake, and (2) measurement of blood cholesterol and neutral lipids. It proceeded with this.
사육이 끝난 실험동물은 12 시간 절식시킨 후 에테르(Ether)를 흡입시켜 마취시킨 다음 복부 하대정맥으로부터 채혈하였으며, 헤파린을 처리하여 원심분리(15 mins, 3,000 RPM)로 혈장을 분리하여 지질함량을 측정하였다.After breeding, the experimental animals were fasted for 12 hours, anesthetized by inhaling ether, and then blood was collected from the inferior vena cava of the abdomen. After treatment with heparin, plasma was separated by centrifugation (15 mins, 3,000 RPM) and lipid content was measured. did.
각 실험동물의 내장(간, 부고환, 신장)을 혈액채취 후 즉시 적출하여 PBS(Phosphate Buffered saline) 용액으로 수차례 헹군 후 표면 수분을 제거하여 비교 정량하였다. 혈장 중성지질은 McGowan 등(1983)의 효소법을 이용한 발색방식의 중성지방 측정용 시액(Asan kit)를 사용하여 550 nm에서 흡광도를 측정하였으며, 혈장 총콜레스테롤은 Allain 등(1974)의 효소법을 응용한 총콜레스테롤 측정용 시액(Asan kit)를 사용하여 발색처리하여 500 nm에서 흡광도를 측정하여 이를 콜레스테롤 표준곡선과 비교 정량하는 방식으로 하였으며, 장기의 지질은 Folch 등(1957)의 방법으로 잘게 자른 후 2 ml, Chloroform: Methyl alcohol 2:1 용액하에서 추출하여 중성지질, 콜레스테롤은 혈장에서와 동일 방법으로 정량하였다. 각 항목은 통계처리하여 평균값으로 하였다. The internal organs (liver, epididymis, kidney) of each experimental animal were removed immediately after blood collection, rinsed several times with PBS (Phosphate Buffered saline) solution, surface moisture was removed, and compared and quantified. Plasma neutral lipids were measured at 550 nm using a colorimetric neutral fat measurement reagent (Asan kit) using the enzymatic method of McGowan et al. (1983), and plasma total cholesterol was measured using the enzymatic method of Allain et al. (1974). A reagent for measuring total cholesterol (Asan kit) was used to develop color, and the absorbance was measured at 500 nm for quantification by comparing it with the cholesterol standard curve. Organ lipids were cut into small pieces using the method of Folch et al. (1957) and then quantified. ml, Chloroform: Methyl alcohol was extracted in a 2:1 solution, and neutral lipids and cholesterol were quantified using the same method as in plasma. Each item was statistically processed and taken as an average value.
(1) 체중변화(1) Weight change
실험동물의 체중변화 및 식이섭취량을 하기 표 6 및 7에 각각 나타내었다. The weight change and dietary intake of the experimental animals are shown in Tables 6 and 7, respectively.
하기 표 6을 참조하면, 실시예 1로부터 제조된 조성물을 경구 급여한 실험동물의 경우 실험전에 비하여 체중이 유사 또는 저하되었고, 반면, 일반식이를 경구 급여한 실험동물 및 정상군의 경우 실험전에 비하여 체중이 증가했음을 확인할 수 있다.Referring to Table 6 below, in the case of experimental animals orally fed the composition prepared in Example 1, the body weight was similar or decreased compared to before the experiment, while in the case of the experimental animals orally fed a normal diet and the normal group, the body weight was compared to before the experiment. You can see that your weight has increased.
하기 표 7을 참조하면, 실시예 1로부터 제조된 조성물 및 일반식이를 경구 급여한 실험동물 및 정상군의 식이섭취량은 모두 유사한 것으로 확인하였다.Referring to Table 7 below, it was confirmed that the dietary intakes of the experimental animals and the normal group orally fed the composition prepared in Example 1 and the normal diet were all similar.
이를 통하여 모든 실험동물의 식이 섭취량이 유사함에도 불구하고, 실시예 1의 조성물을 섭취한 실험동물의 체중이 모두 증가하지 않고, 실험 전과 유사하거나 실험전에 비하여 감소하여 다이어트 식품으로서 활용 가능함을 확인하였다.Through this, despite the fact that the dietary intake of all the experimental animals was similar, the body weight of all the experimental animals that consumed the composition of Example 1 did not increase, but was similar to or decreased compared to before the experiment, confirming that it can be used as a diet food.
(2) 혈중 콜레스테롤 및 중성지질(2) Blood cholesterol and neutral lipids
실험동물의 혈장 중성지질, 혈장 콜레스테롤, 부고환 중성지질, 신장 조직의 중성지질 및 간조직에서의 콜레스테롤을 하기 표 8 및 9에 나타내었다.The plasma neutral lipids, plasma cholesterol, epididymal neutral lipids, renal tissue neutral lipids, and liver tissue cholesterol of the experimental animals are shown in Tables 8 and 9 below.
하기 표 8을 참조하면, 실시예 1의 조성물을 섭취한 시험대조군은 실험전에 비해 혈장 중성지질이 현저히 감소한 반면, 일반식이를 섭취한 시험대조군은 유의적인 변화가 나타나지 않았다.Referring to Table 8 below, the test control group that consumed the composition of Example 1 had a significant decrease in plasma neutral lipids compared to before the experiment, while the test control group that consumed the regular diet showed no significant change.
하기 표 9를 참조하면, 실시예 1의 식품 조성물을 섭취한 시험대조군은 실험전에 비해 혈장 콜레스테롤이 현저히 감소한 반면, 일반식이는 유의적인 변화가 나타나지 않았음을 확인할 수 있다.Referring to Table 9 below, it can be seen that the test control group that consumed the food composition of Example 1 had a significant decrease in plasma cholesterol compared to before the experiment, while the regular diet showed no significant change.
상기 결과를 통하여, 본 발명에 따른 실시예 1에서 제조된 조성물은 중성지질의 양의 감소현상을 확인할 수 있어 지방과 콜레스테롤을 개선시키는 특징을 확인하였다. Through the above results, the composition prepared in Example 1 according to the present invention was confirmed to have the characteristic of improving fat and cholesterol by confirming a decrease in the amount of neutral lipids.
<시험예 6> 세포독성 시험<Test Example 6> Cytotoxicity test
대식세포주인 RAW 264.7 세포는 한국세포주은행(KTCC)에서 분양받아 10% FBS(fetalbovine serum), 1% 항생제, 2-ME(2-mercaptoethanol)를 함유한 RPMI 1640 배지를 이용하여 37℃, 4% CO2에서 조절된 인큐베이터에서 배양하였다.RAW 264.7 cells, a macrophage cell line, were purchased from the Korea Cell Line Bank (KTCC) and cultured at 37°C using RPMI 1640 medium containing 10% FBS (fetalbovine serum), 1% antibiotics, and 2-mercaptoethanol (2-ME) at 4% CO. Cultured in an incubator controlled at CO 2 .
상기 배양된 마우스의 대식세포주 RAW264.7를 96웰 플레이트에 well당 5 X 104 cells/100 μl씩 분주한 뒤, 24 시간 동안 CO2 배양하였다. LPS (lipopolysaccharide)를 1 μg/ml 농도로 처리한 후 1시간 뒤, 상기 실시예 1에서 제조된 조성물 시료를 처리하고 24시간 동안 CO2 배양하였다. 그 다음 배양 상층액을 각각 100 μl씩 제거하고, CCK-8 시약을 10 μl씩 처리하여 3시간 CO2 배양한 뒤에 마이크로플레이트 리더기를 이용하여 450nm에서 흡광도를 측정하였다. The cultured mouse macrophage cell line RAW264.7 was dispensed into a 96 -well plate at 5 One hour after treatment with LPS (lipopolysaccharide) at a concentration of 1 μg/ml, the sample of the composition prepared in Example 1 was treated and incubated in CO 2 for 24 hours. Next, 100 μl of each culture supernatant was removed, and 10 μl of CCK-8 reagent was treated, incubated in CO 2 for 3 hours, and then the absorbance was measured at 450 nm using a microplate reader.
그 결과는 하기 표 10에 나타내었다.The results are shown in Table 10 below.
결과에서 보듯이, 시료가 세포독성을 나타내는지 실험시료를 LPS로 활성화된 대식세포주 (RAW264.7)에 처리하여 확인한 결과, 본 발명의 조성물은 독성을 나타내지 않는 것을 확인하였다.As shown in the results, it was confirmed whether the sample exhibited cytotoxicity by treating the experimental sample with a macrophage cell line (RAW264.7) activated with LPS, and it was confirmed that the composition of the present invention does not exhibit toxicity.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (5)
상기 기능성 식품 조성물은 치커리 추출물 100 중량부에 대하여 늙은 호박 발효물 50 내지 70 중량부 및 차전자피 분말 30 내지 50 중량부를 포함하는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물.According to claim 1,
The functional food composition contains 50 to 70 parts by weight of aged pumpkin fermentation and 30 to 50 parts by weight of psyllium husk powder based on 100 parts by weight of chicory extract. Antioxidation, blood circulation improvement, anti-obesity, immune function and organ function enhancement. An effective functional food composition.
상기 치커리 추출물은 치커리를 동결건조하고 분쇄하여 90 내지 110℃의 정제수를 이용하여 50 내지 70분 동안 열수 추출한 다음 감압 여과 및 농축하여 수득되는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물.According to claim 1,
The chicory extract is obtained by freeze-drying and pulverizing chicory, hot water extraction for 50 to 70 minutes using purified water at 90 to 110 ° C., followed by reduced pressure filtration and concentration. Antioxidant, blood circulation improvement, anti-obesity, immune function. and functional food compositions with long-term function strengthening effects.
상기 치커리는 치커리 뿌리를 이용하는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물.According to claim 1,
The chicory is a functional food composition having antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening effects, characterized by using chicory root.
상기 늙은 호박 발효물은 37 내지 45℃에서 24 내지 48시간 동안 발효시켜 수득되는 것을 특징으로 하는 항산화, 혈액순환 개선, 항비만, 면역기능 및 장기기능 강화효과를 가지는 기능성 식품 조성물.According to claim 1,
The aged pumpkin fermentation product is a functional food composition having antioxidant, blood circulation improvement, anti-obesity, immune function and organ function strengthening effects, characterized in that it is obtained by fermenting at 37 to 45 ° C. for 24 to 48 hours.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20220043399 | 2022-04-07 | ||
KR1020220043399 | 2022-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230144935A true KR20230144935A (en) | 2023-10-17 |
Family
ID=88557780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230001026A KR20230144935A (en) | 2022-04-07 | 2023-01-04 | Functional food composition comprising chicory extracts, aged pumpkin fermentation and psyllium husk powder |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230144935A (en) |
-
2023
- 2023-01-04 KR KR1020230001026A patent/KR20230144935A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2520207C (en) | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease | |
JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
JP5685752B2 (en) | Blood flow promoting agent | |
CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
JP4432069B2 (en) | Obesity inhibitor | |
Ferrara | Nutritional and pharmacological properties of Tamarindus indica L | |
KR102305931B1 (en) | A food composition for improving circulation of blood and increasing functions of immune comprising natural extracts | |
KR101559888B1 (en) | Composition for improving hepatoprotective activity comprising fermented garlic extracts | |
KR100699782B1 (en) | Food composition for improving liver function comprising a Lonicera caerulea L. var. edulis extract | |
KR20180042936A (en) | a composition comprising the mycelium culture medium from Schizophyllum commune as an active ingredient for preventing or treating liver disease and alleviating hangover | |
KR20220067467A (en) | A composition comprising the ethanol extract of Corchorus olitorius for the prevention or treatment of alcoholic liver damage | |
KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR20230144935A (en) | Functional food composition comprising chicory extracts, aged pumpkin fermentation and psyllium husk powder | |
JP7296611B2 (en) | Nitric oxide production accelerator | |
KR102085713B1 (en) | Method for producing vinegar foaming tablet for diet | |
JP2010043036A (en) | Saccharometabolism promoter | |
KR20200120549A (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
KR102621205B1 (en) | An anti-oxidant and anti-inflammatory composition comprising extracts of lacquer tree, fluafomitella fraxinea and kudingcha | |
KR20190084732A (en) | A composition for improving, preventing and treating obesity comprising fermented pollack skin | |
KR100803385B1 (en) | Composition and food for prevention of disease to nerve system with extracts of Wasabia japonica | |
KR102499700B1 (en) | Functional composition comprising lactic acid bacteria, propolis, vitamins and collagen | |
KR20190037014A (en) | Composition for eliminating hangover comprising fermented liquor of aged sprout ginseng extract as effective component | |
KR20190021614A (en) | Composition for antioxidant, antiinflammatory and inflammatory neurodegenerative diseases comprising perilla frutescens britton extract | |
KR20240019415A (en) | Method for producing fermented chinese matrimony vine powder and fermented chinese matrimony vine powder prepared therefrom |